11. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of:

|	
KGVSPSYRCPCRFFESH	(SEQ ID No. 18)
KGVSLPYRCPCRFFESH	(SEQ ID No. 19)
KGVSLSPRCPCRFFESH	(SEQ ID No. 20)
KGVSLSYPCPCRFFESH	(SEQ ID No. 21)
KGVSP*SYRCPCRFFESH	(SEQ ID No. 22)
KGVSLP*YRCPCRFFESH	(SEQ ID No. 23)
KGVSLSP*RCPCRFFESH	(SEQ ID No. 24)
KGVSLSYP*CPCRFFESH	(SEQ ID No. 25)
KGVSBtdYRCPCRFFESH	(SEQ ID No. 26)
KGVSLBtdRCPCRFFESH	(SEQ ID No. 27)
KGVSLSBtdCPCRFFESH	(SEQ ID No. 28)
KGVSPSYRC	(SEQ ID No. 29)
KGVSLPYRC	(SEQ ID No. 30)
KGVSLSPRC	(SEQ ID No. 31)
KGVSLSYPC	(SEQ ID No. 32)
KGVSP*SYRC	(SEQ ID No. 33)
KGVSLP*YRC	(SEQ ID No. 34)
KGVSLSP*RC	(SEQ ID No. 35)
KGVSLSYP*C	(SEQ ID No. 36)

- 14 -

KGVSBtdYRC　　　　　　　(SEQ ID No. 37)

KGVSLBtdRC　　　　　　　(SEQ ID No. 38)

KGVSLSBtdC　　　　　　　(SEQ ID No. 39)

wherein P* =


with X= Ar, Ar-OH, alkyl and more

and Btd =

X= Alkyl, Ar, Ar-OH and more

[Please amend claim 12 as follows:]
　　　12. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of (SEQ ID Nos. 40-50):

KGVSPSYRC	KGVSLPYRC	KGVSLSPRC	KGVSLSYPC
|	|	|	|
KGVSPSYRC	KGVSLPYRC	KGVSLSPRC	KGVSLSYPC

KGVSP*SYRC	KGVSLP*YRC	KGVSLSP*RC	KGVSLSYP*C
|	|	|	|
KGVSP*SYRC	KGVSLP*YRC	KGVSLSP*RC	KGVSLSYP*C

KGVSBtdYRC	KGVSLBtdRC	KGVSLSBtdC
|	|	|
KGVSBtdYRC	KGVSLBtdRC	KGVSLSBtdC

wherein P* =

with X= Ar, Ar-OH, alkyl and more

and Btd =

X= Alkyl, Ar, Ar-OH and more

Please amend claim 13 as follows:

13. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of (SEQ ID Nos. 51-72):

KGVSPSYR   KGVSLPYR   KGVSLSPR   KGVSLSYP
     | | | |
     X   X   X   X
     | | | |
KGVSPSYR   KGVSLPYR   KGVSLSPR   KGVSLSYP

KGVSP*SYR   KGVSLP*YR   KGVSLSP*R   KGVSLSYP*
     | | | |
     X   X   X   X
     | | | |
KGVSP*YR   KGVSLP*YR   KGVSLSP*R   KGVSLSYP*

KGVSBtdYR   KGVSLBtdR   KGVSLSBtd
     | | |
     X   X   X
     | | |
KGVSBtdYR   KGVSLBtdR   KGVSLSBtd

wherein X is a natural or unnatural amino acid linker between each of the arginines at position 8 in each sequence; and,

wherein P* =

with X= Ar, Ar-OH, alkyl and more

and Btd =

or

or

X= Alkyl, Ar, Ar-OH and more

[Please amend claim 14 as follows:]
    14. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected

- 17 -

from the group consisting of:

KGVSLSYRCPCRFF-G_n-LKWIQEYLEKALN   (SEQ ID No. 74)

KGVSLSYRCPCRFFESH-G_n-LKWIQEYLEKALN   (SEQ ID No. 75)

wherein n is an integer from 0 to 10.

(Please amend claim 15 as follows:\

    15. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected

    from the group consisting of:

KGVSLSYRCPCRFF-$(CH_2)_n$–LKWIQEYLEKALN   (SEQ ID No. 76)

KGVSLSYRCPCRFFESH-$(CH_2)_n$-LKWIQEYLEKALN   (SEQ ID No. 77)

where n is an integer from 1 to 20.

(Please amend claim 16 as follows:\

    16. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected

    from the group consisting of:

KGVSPSYRCPCRFF-GGGG-LKWIQEYLEKALN   (SEQ ID No.78);

KGVSLPYRCPCRFF-GGGG-LKWIQEYLEKALN   (SEQ ID No.79);

KGVSLSPRCPCRFF-GGGG-LKWIQEYLEKALN   (SEQ ID No.80);

KGVSLSYPCPCRFF-GGGG-LKWIQEYLEKALN   (SEQ ID No.81);

KGVSPSYRCPCRFFESH-GGGG-LKWIQEYLEKALN   (SEQ ID No.82);

KGVSLPYRCPCRFFESH-GGGG-LKWIQEYLEKALN   (SEQ ID No.83);

KGVSLSPRCPCRFFESH-GGGG-LKWIQEYLEKALN   (SEQ ID No.84);

KGVSLSYPCPCRFFESH-GGGG-LKWIQEYLEKALN   (SEQ ID No.85);

KGVSPSYRCPCRFF-$(CH_2)_n$–LKWIQEYLEKALN   (SEQ ID No.86);

KGVSLPYRCPCRFF-$(CH_2)_n$–LKWIQEYLEKALN   (SEQ ID No.87);

KGVSLSPRCPCRFF-$(CH_2)_n$–LKWIQEYLEKALN   (SEQ ID No.88);

KGVSLSYPCPCRFF-$(CH_2)_n$–LKWIQEYLEKALN   (SEQ ID No.89);

KGVSPSYRCPCRFFESH-$(CH_2)_n$–LKWIQEYLEKALN   (SEQ ID No.90);

KGVSLPYRCPCRFFESH-$(CH_2)_n$–LKWIQEYLEKALN   (SEQ ID No.91);

KGVSLSPRCPCRFFESH-$(CH_2)_n$–LKWIQEYLEKALN   (SEQ ID No.92);

KGVSLSYPCPCRFFESH- $(CH_2)_n$ –LKWIQEYLEKALN (SEQ ID No.93),

wherein n is an integer from 1 to 20.

[Please amend claim 17 as follows:]

17. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of:

KGVSP*SYRCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No. 94);

KGVSLP*YRCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No. 95);

KGVSLSP*RCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No. 96);

KGVSLSYP*CPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No. 97);

KGVSP*SYRCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 98);

KGVSLP*YRCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 99);

KGVSLSP*RCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 100);

KGVSLSYP*CPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 101);

KGVSP*SYRCPCRFF-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 102);

KGVSLP*YRCPCRFF-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 103);

KGVSLSP*RCPCRFF-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 104);

KGVSLSYP*CPCRFF-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 105);

KGVSP*SYRCPCRFFESH-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 106);

KGVSLP*YRCPCRFFESH-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 107);

KGVSLSP*RCPCRFFESH-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 108);

KGVSLSYP*CPCRFFESH-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 109);

KGVSBtdYRCPCRFF-GGGG-LKWIQEYLEKALN   (SEQ ID No. 110);

KGVSLBtdRCPCRFF-GGGG-LKWIQEYLEKALN   (SEQ ID No. 111);

KGVSLSBtdCPCRFF-GGGG-LKWIQEYLEKALN   (SEQ ID No. 112);

KGVSBtdYRCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 113);

KGVSLBtdRCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 114);

KGVSLSBtdCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 115);

KGVSBtdYRCPCRFF-$(CH_2)_n$–LKWIQEYLEKALN   (SEQ ID No. 116);

KGVSL**Btd**RCPCRFF-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 117);

KGVSLS**Btd**CPCRFF-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 118);

KGVS**Btd**YRCPCRFFESH-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 119);

KGVSL**Btd**RCPCRFFESH-$(CH_2)_n$–LKWIQEYLEKALN (SEQ ID No. 120);

KGVSLS**Btd**CPCRFFESH- $(CH_2)_n$ –LKWIQEYLEKALN (SEQ ID No. 121),

wherein n is an integer from 0 to 20 and

wherein P* =

with X= Ar, Ar-OH, alkyl and more

and Btd =

  or   or

X= Alkyl, Ar, Ar-OH and more

Please amend claim 18 as follows:

18. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of (SEQ ID Nos. 122-125):

KGVSLSYRCPCRFFGGGGLKWIQEYLEKALN
|___|

KGVSLSYRCPCRFFESHGGGGLKWIQEYLEKALN
|___|

KGVSLSYRCPCRFFGGGGLKWIQEYLEKALN
|___|

KGVSLSYRCPCRFFESHGGGGLKWIQEYLEKALN
|___|

[Please claim 19 has been amended as follows:]

19. (Amended) A CXCR4 antagonist peptide selected from the group consisting of (SEQ ID

Nos. 122-125):

KGVSLSYRCPCRFFGGGGLKWIQEYLEKALN
|___|

KGVSLSYRCPCRFFESHGGGGLKWIQEYLEKALN
|___|

KGVSLSYRCPCRFFGGGGLKWIQEYLEKALN
|___|

KGVSLSYRCPCRFFESHGGGGLKWIQEYLEKALN
|___|

[Please amend claim 20 as follows:]

20. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected

from the group consisting of:

KGVSLSYRCPCRFFGGGGSKPGVIFLTKRSRQV (SEQ ID No. 126);

KGVSLSYRCPCRFF(CH$_2$)$_n$ SKPGVIFLTKRSRQV (SEQ ID No. 127);

KGVSLSYRCPCRFFGGGGEEWVQKYVDDLELSA (SEQ ID No. 128);